Bildnachweis: CorTec.
CorTec GmbH, a pioneer in fully implantable brain-computer interfaces (BCI), announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its proprietary Brain Interchange™ System. The designation specifically targets the use of direct cortical electrical stimulation to facilitate motor rehabilitation in patients suffering from chronic stroke-related impairments.
The FDA’s Breakthrough Device programme is reserved for medical technologies that demonstrate the potential to provide more effective treatment for life-threatening or irreversibly debilitating conditions. This status affords CorTec an accelerated regulatory pathway, including prioritised review and enhanced access to FDA experts during the development and pre-market approval stages.
Pioneering Closed-Loop Technology
CorTec’s Brain Interchange System is a high-bandwidth platform that integrates neural signal recording with adaptive, closed-loop stimulation. The system is currently undergoing evaluation in an FDA-approved Investigational Device Exemption (IDE) study at the University of Washington, Seattle. This marks the first clinical investigation of a fully implantable, wireless BCI system designed specifically for human stroke rehabilitation. Stroke remains the leading cause of acquired long-term disability in adults worldwide. Of the approximately 9 million ischaemic strokes occurring annually, 1.7 million are recorded in the US and Europe alone. Despite standard rehabilitation, roughly 50% of survivors suffer from persistent upper-limb impairments. For those in the chronic stage where recovery has plateaued, no approved implantable therapeutic options currently exist. “
Only a few BCI companies worldwide – including Neuralink, Synchron, or Blackrock Neurotech – have received Breakthrough Device Designation to date. Achieving this designation is a defining milestone for CorTec and underscores the potential of our Brain Interchange system to address the significant unmet need in stroke rehabilitation,” said Dr Frank Desiere, CEO of CorTec. “Together with promising initial results from our first-in-human study in Seattle as well as additional long-term data published in Nature Scientific Data1 demonstrating signal stability over 500 days, this designation provides strong momentum as we advance toward larger clinical trials. We believe CorTec occupies a unique position in the global BCI landscape, combining a fully implantable, bidirectional closed-loop platform with a therapeutic approach focused on restoring motor function after stroke.”
Differentiation and Market Positioning
While other BCI firms have gained traction primarily in assistive communication (allowing patients to control digital devices), CorTec’s approach is fundamentally therapeutic. The Brain Interchange™ platform is engineered to go beyond communication, enabling neurostimulation to physically restore motor function. CorTec currently stands as the only BCI company worldwide to hold a Breakthrough Designation for this specific indication. Mara Assis, Head of Regulatory Affairs & Quality Management at CorTec, added:
„The Breakthrough Device Designation enables more frequent and structured engagement with the FDA as we advance our development program. Our regulatory strategy has followed a stepwise approach, from prior device clearance to IDE approval and successful human implantations. This designation will help accelerate planning of clinical trials and support the next regulatory milestones.”
Future Outlook
CorTec continues to position its Brain Interchange System as a versatile, adaptive platform with multi-indication potential. Beyond the flagship stroke rehabilitation programme, the technology is being evaluated for epilepsy, with further applications for paralysis and depression currently in the R&D pipeline.
